Advertisement
GSK vs NVS
Which Stock Would AI Choose? GSK plc (GSK) vs. Novartis AG (NVS) Stock Comparison
1) Key Takeaways
- GSK is executing a pipeline-acceleration strategy under new leadership, combining a £1.9 billion cost-savings program with plans to start more than 20 late-stage (Phase III) trials in 2026.
- NVS offers a larger scale and a higher-growth oncology and cardiovascular franchise, but it is navigating substantial patent expirations and a pair of recent Phase III setbacks.
- Both companies generate the majority of their revenue in the United States, making them sensitive to U.S. drug-pricing policy and broader healthcare demand trends.
- GSK trades at a lower valuation with a higher dividend yield, while NVS commands a premium market capitalization with a diversified specialty-medicine portfolio.
- Relative performance has diverged: GSK has shown stronger year-over-year momentum, while NVS has pulled back from its 52-week high on pipeline disappointments.
2) Introduction
This stock comparison examines two of the world's leading pharmaceutical companies: GSK plc, headquartered in the United Kingdom, and Novartis AG, based in Switzerland. Both are bellwethers of the global healthcare sector, yet they sit at different points in their strategic cycles. GSK is rebuilding momentum around specialty medicines and vaccines, while Novartis is leaning on high-growth oncology and cardiovascular assets to offset looming patent cliffs. For investors and traders evaluating market positioning within defensive healthcare, this relative performance review highlights the contrasting risk profiles, growth drivers, and valuation dynamics that distinguish these two large-cap names in the current environment.
3) GSK Overview and Recent Performance
GSK plc (GlaxoSmithKline) develops medicines, vaccines, and specialty treatments across respiratory, oncology, HIV, and immunology. Under new Chief Executive Officer Luke Miels, who assumed the role at the start of 2026, the company has sharpened its focus on late-stage pipeline execution. In recent weeks, GSK reported second-quarter results that exceeded consensus expectations, with revenue of roughly £8.4 billion and specialty-medicine sales rising at a double-digit pace. Management simultaneously unveiled a £1.9 billion annual cost-savings program to be achieved by 2029, reinvesting the bulk of those savings into research and development.
Sentiment has been shaped by a balancing act: strong growth in oncology and HIV franchises against the approaching loss of exclusivity on dolutegravir, its leading HIV treatment, expected between 2028 and 2030. The company has also reaffirmed full-year guidance for sales growth of 3% to 5% and core earnings-per-share growth of 7% to 9%, alongside a longer-term ambition of surpassing £40 billion in annual revenue by 2031. After a strong run over the past year, GSK shares have consolidated below their 52-week high as investors weigh the cost of its acceleration plan.
4) NVS Overview and Recent Performance
Novartis AG is a Swiss pharmaceutical group focused on innovative prescription medicines across four core areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease. The company has delivered robust growth from key brands, including Kisqali (breast cancer), Pluvicto (prostate cancer), Kesimpta (multiple sclerosis), Leqvio (cholesterol), and Scemblix (leukemia), several of which posted strong double-digit sales gains in recent quarters. Novartis also recently secured U.S. Food and Drug Administration (FDA) approval for Rhapsido in a new indication, expanding its immunology franchise.
However, near-term performance has been tempered by generic erosion on established drugs such as Entresto and Promacta, as well as back-to-back Phase III trial failures for the experimental medicines pelacarsen and del-desiran reported in recent weeks. These setbacks pressured shares from their 52-week high, even as the company continues a sizable share-buyback program and pursues acquisitions and licensing deals to bolster its pipeline. Novartis maintains a strong credit profile and reiterated a low-single-digit sales-growth outlook for the year.
5) Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers across diverse strategies, timeframes, and risk profiles. Because not every bot is suited to every market regime, Tickeron curates only the strongest performers into its Trending AI Robots section, where users can review the bots best aligned with current conditions. These bots vary widely in style — from short-term momentum and swing strategies to longer-horizon trend-following approaches — and each carries its own historical performance statistics, win rates, and trade frequency. For investors comparing GSK and NVS, exploring these curated tools can provide a data-driven perspective on how algorithmic models are positioning across the healthcare sector. Review the available bots to see which align with your own analytical framework.
6) Head-to-Head Comparison
The two companies differ most clearly in scale and focus. Novartis is the larger business by market capitalization and operates a more concentrated specialty portfolio, with oncology and cardiovascular-renal-metabolic drugs driving an outsized share of growth. GSK, by contrast, retains a meaningful vaccines and general-medicines franchise that diversifies its revenue mix but exposes it to different demand cycles, such as vaccination uptake trends.
On growth drivers, NVS currently benefits from a broader set of rapidly scaling products, while GSK is investing heavily to accelerate its pipeline and offset an approaching HIV patent expiry. Risk factors also diverge: NVS faces near-term generic competition and recent clinical disappointments, whereas GSK's key risk is the dolutegravir loss of exclusivity later this decade and the execution cost of its efficiency program. From a valuation standpoint, GSK trades at a lower price-to-earnings multiple and offers a higher dividend yield, while NVS carries a premium valuation supported by its growth-asset momentum. Market sentiment has favored GSK's renewed execution story in recent months, even as NVS retains analyst support for its longer-term growth trajectory.
7) Tickeron AI Verdict
Based on observable factors such as trend consistency, relative momentum, and near-term catalysts, Tickeron's AI would likely lean toward GSK in the current environment. GSK has demonstrated steadier recent price behavior, delivered consensus-beating results, and introduced a clearly defined cost and pipeline strategy that provides visible catalysts over the next several quarters. In contrast, NVS faces more immediate headwinds from generic erosion and recent trial failures, which have weighed on its trend stability despite strong underlying product growth. This assessment is probabilistic and reflects relative positioning rather than a definitive forecast; both stocks carry distinct risks and may appeal to different investor profiles depending on their tolerance for volatility and their investment horizon.
8) Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Hold and NVS is a Hold.
GSK in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 01, 2026
GSK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 40 cases where GSK's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GSK's RSI Indicator exited the oversold zone, 16 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on GSK as a result. In 53 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for GSK just turned positive on October 15, 2026. Looking at past instances where GSK's MACD turned positive, the stock continued to rise in 31 of 46 cases over the following month. The odds of a continued upward trend are 67%.
Following a +3.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in 202 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
GSK moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Aroon Indicator for GSK entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.266) is normal, around the industry mean (19.199). P/E Ratio (15.948) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (6.052) is also within normal values, averaging (5.738). Dividend Yield (0.037) settles around the average of (0.025) among similar stocks. P/S Ratio (2.294) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 42 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
NVS's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for NVS turned positive on September 24, 2026. Looking at past instances where NVS's MACD turned positive, the stock continued to rise in 30 of 46 cases over the following month. The odds of a continued upward trend are 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NVS's RSI Indicator exited the oversold zone, 15 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVS as a result. In 37 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 46%.
NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 182 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 162 of 318 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
NVS broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.720) is normal, around the industry mean (19.199). P/E Ratio (22.187) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). Dividend Yield (0.032) settles around the average of (0.025) among similar stocks. P/S Ratio (4.715) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 7 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating fairly steady price growth. NVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
GSK | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 17 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 42 | 7 | |
SMR RATING 1..100 | 34 | 33 | |
PRICE GROWTH RATING 1..100 | 56 | 45 | |
P/E GROWTH RATING 1..100 | 56 | 21 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (4) in the Pharmaceuticals Major industry is in the same range as GSK (5). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.
NVS's Profit vs Risk Rating (7) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (42). This means that NVS’s stock grew somewhat faster than GSK’s over the last 12 months.
NVS's SMR Rating (33) in the Pharmaceuticals Major industry is in the same range as GSK (34). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.
NVS's Price Growth Rating (45) in the Pharmaceuticals Major industry is in the same range as GSK (56). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.
NVS's P/E Growth Rating (21) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (56). This means that NVS’s stock grew somewhat faster than GSK’s over the last 12 months.
| GSK | NVS | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 70% | 5 days ago 63% |
| Stochastic ODDS (%) | 3 days ago 32% | 3 days ago 41% |
| Momentum ODDS (%) | 3 days ago 71% | 3 days ago 46% |
| MACD ODDS (%) | 3 days ago 67% | 3 days ago 65% |
| TrendWeek ODDS (%) | 3 days ago 64% | 3 days ago 54% |
| TrendMonth ODDS (%) | 3 days ago 53% | 3 days ago 51% |
| Advances ODDS (%) | 3 days ago 63% | 3 days ago 54% |
| Declines ODDS (%) | 10 days ago 55% | 13 days ago 45% |
| BollingerBands ODDS (%) | 3 days ago 73% | 3 days ago 32% |
| Aroon ODDS (%) | 3 days ago 43% | 3 days ago 51% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 1 FA rating(s) are green while NVS’s FA Score has 4 green FA rating(s).
- GSK’s FA Score: 1 green, 4 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 5 TA indicator(s) are bullish while NVS’s TA Score has 6 bullish TA indicator(s).
- GSK’s TA Score: 5 bullish, 4 bearish.
- NVS’s TA Score: 6 bullish, 4 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а +6.47% price change this week, while NVS (@Pharmaceuticals: Major) price change was +4.78% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.91%. For the same industry, the average monthly price growth was -4.47%, and the average quarterly price growth was +3.55%.
Reported Earning Dates
GSK is expected to report earnings on Oct 28, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.91% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement